German antibody‑drug conjugate specialist Tubulis closed a $361 million Series C to advance its clinical ADC programs and expand manufacturing and R&D capabilities. The financing positions the company to accelerate IND filings and late preclinical work on its linker‑payload platforms that aim for improved stability and therapeutic index. The round — one of the largest dedicated to ADC development — reflects investor appetite for differentiated payload/linker chemistry and for companies that promise more tolerable, efficacious targeted cytotoxics in solid tumors.